Clinical trial
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)
NCT05945732 is registered in ClinicalTrials.gov with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- October 24, 2023
- Completion date
- December 31, 2030
- Enrollment
- 2,295 (estimated)
- Sites
- 216
Conditions
As the registry lists them; a condition with its own page is linked.
her2-(ultra)low expressing breast cancer, her2-low expressing breast cancer, metastatic breast cancer, unresectable breast cancer